MedPath

comparison the effect of two kind of HCG in IVF cycle

Not Applicable
Conditions
female infertility.
???????? ????
Registration Number
IRCT201107034339N2
Lead Sponsor
Yazd University of Medical Sciences
Brief Summary

Background: Human chorionic gonadotropin (HCG) has been used as a replacement for the mid-cycle luteinizing hormone (LH) surge for several years. The recent arrival of recombinant DNA technology has made recombinant HCG (rHCG) accessible. Objective: To assess efficacy of rHCG compared to urinary HCG (uHCG) for triggering of ovulation and induction of final oocyte maturation in assisted reproductive cycles. Materials and Methods: 200 patients who were candidate for ICSI were randomly divided in two groups. In group I (rHCG), patients received 250µg of rHCG for final oocyte maturation, and in group II (uHCG) the patients received 10000 IU of uHCG. Measured outcomes were number of retrieved oocyte and mature oocyte, maturation rate of oocyte, fertilization rate and clinical pregnancy rate. Results: The rates of oocyte maturity were similar in both groups. Fertilization rate was similar in two groups (58.58% in rHCG group versus 60.58% in uHCG group p=0.666). The clinical pregnancy rate per cycle was similar in both group 34.0% in rHCG group versus 39% in uHCG group (p=0.310). Conclusion: We demonstrated that rHCG is as effective as uHCG, when it is used for final oocyte maturation in ICSI cycles. The numbers of retrieved oocyte and maturation rates were similar in both groups; also fertilization and clinical pregnancy rates were similar.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
200
Inclusion Criteria

regular menstrual cycles
age<38 years old
FSH<10 IU/L
BMI<30kg/m2

Exclusion Criteria

history of metabolic or endocrine disorder
history of pelvic surgery
severe male factor infertilitywhich was defined as severe oligospermia (<5million sperm/ml),asthenospermia (5% progressive motility),or teratospermia (4% normal forms by strict criteria).

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
umber and maturity of oocyte. Timepoint: ovum pick up. Method of measurement: by microscope.
Secondary Outcome Measures
NameTimeMethod
Chemical pregnancy. Timepoint: 14 days after embryo transfer. Method of measurement: blood.
© Copyright 2025. All Rights Reserved by MedPath